NYSE:ABBVBiotechs
Assessing AbbVie (ABBV) Valuation After Rinvoq Exclusivity Extension Secures Key Revenue Driver
If you are trying to figure out what to do with your AbbVie (ABBV) shares, the most recent development might catch your eye. The company just settled with generic drugmakers to resolve all litigation over its autoimmune blockbuster, Rinvoq, extending U.S. market exclusivity for the drug until at least April 2037. This isn’t just a headline for industry insiders; it is a game-changer for the revenue outlook, and it matters to anyone thinking seriously about the stock.
In the context of this...